Does RNA-based inhibition of apo C-III improve outcomes in patients with familial chylomicronemia syndrome?
RNA-based apo C-III inhibitors offer a transformative therapeutic option for FCS by lowering triglycerides and reducing pancreatitis risk.
Differentiating FCS from MCS is critical because RNA-based inhibition of apo C-III has transformed the therapeutic landscape for FCS patients. These agents provide substantial, durable TG lowering and meaningful reductions in pancreatitis risk, although cardiovascular benefit remains uncertain. Future efforts should focus on optimizing diagnostic pathways, assessing cardiovascular outcomes, and determining long-term safety of novel biologic therapies.
Hang et al. (Mon,) studied this question.